 Alexion Pharmaceuticals Inc NASDAQ: ALXN announced topline results from a Phase 3 study evaluating Ultomiris ravulizumab-cwvz in adults with generalized myasthenia gravis gMG. The study met its primary endpoint, with a statistically significant change in MG-ADL score from baseline through Week 26 for Ultomiris compared to placebo -3.1 versus -1.4. 